Pharmaceuticals (Basel, Switzerland)
Leveraging Acquired EGFR-TKI-Resistant Models to Identify MUC16 as a Therapeutic Vulnerability in Lung Adenocarcinoma.
Yinhua Tan, Chunxiu Xiao, Zhifan Wang, Yuhang Kong, Yamei Huang, Zhichang Liu, Qiang Wu, Chenyu Wu, Manyu Zhao, Jingyao Chen, Kai Xiao
Published: 202510.3390/ph19010047
Abstract
Background/Objectives: Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) remains a major challenge in the treatment of EGFR-mutant lung adenocarcinoma (LUAD). This study aimed to develop and characterize…
Preview only. Read the full abstract at the source